NASDAQ$PACB
Pacific Biosciences of California Inc · Q2 2024 earnings
Q2 2024 earnings · · Investor relations
Briefing
PACB Q2 2024 — $19.2M revenue, 0.64 EPS
December 31, 2023 audited consolidated financial statements and include all adjustments, consisting of only normal recurring adjustments, necessary to fairly state our financial position, results of o. Pacific Biosciences of California Inc reported Q2 2024 results. Diluted EPS came in at $0.64. Headline numbers extracted from the Form 10-Q press release; narrative is light because this row was processed without an LLM call.
- Revenue: $19.2M.
- Diluted EPS: $0.64.
- Operating income: $176K.
- Gross profit: $6K.
Headline financials
Revenue & EPS history
Pacific Biosciences · Revenue · Quarterly
$36M
Revenue by segment
Pacific Biosciences · $47.6M total across 3 segments · Q2 2023
- Instrument Revenue$24.7M+42.0%51.9%
- Consumables Revenue$17.9M+29.7%37.6%
- Service & Other Revenue$5M+150.0%10.5%
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q2 2024
+1.6%
Avg return
Earnings day
+2.4%
Avg return
5 days after
+4.1%
Avg return
30 days after
47%
29 / 62 earnings
Positive
+69.9%
Q3 2018
Best reaction
-27.2%
Q3 2017
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -14.5% | -23.0% | -12.7% | |
| Q4 2025 | -7.1% | -11.4% | -27.7% | |
| Q3 2025 | -1.1% | -2.2% | +34.3% | |
| Q1 2025 | -8.4% | -8.3% | -5.0% | |
| Q4 2024 | +25.0% | +19.6% | -17.6% | |
| Q3 2024 | -13.2% | -16.6% | -23.4% | |
| Q2 2024 | +4.4% | -10.6% | -1.2% | |
| Q1 2024 | +5.4% | +32.7% | +19.6% | |
| Q4 2023 | +9.7% | -18.6% | -41.7% | |
| Q3 2023 | +20.9% | +15.2% | +48.7% | |
| Q2 2023 | -0.7% | -3.7% | -13.3% | |
| Q1 2023 | -2.8% | -0.5% | +13.6% | |
| Q4 2022 | +5.1% | -17.6% | -25.2% | |
| Q3 2022 | +2.1% | +11.8% | +31.9% | |
| Q2 2022 | +11.4% | +27.4% | -10.3% | |
| Q1 2022 | -4.5% | +2.9% | -7.1% | |
| Q4 2021 | +8.2% | +4.5% | -0.5% | |
| Q3 2021 | +6.6% | +5.3% | -22.1% | |
| Q2 2021 | +5.5% | +4.1% | +0.2% | |
| Q1 2021 | -0.2% | -3.4% | +4.7% | |
| Q4 2020 | +29.4% | +27.3% | -14.3% | |
| Q3 2020 | +16.1% | +18.2% | +62.7% | |
| Q2 2020 | -3.1% | +1.0% | +66.5% | |
| Q1 2020 | +9.4% | +11.6% | +26.7% | |
| Q4 2019 | -4.1% | -12.3% | -16.3% | |
| Q3 2019 | -2.8% | -4.8% | +3.5% | |
| Q2 2019 | +3.5% | +5.6% | +4.1% | |
| Q1 2019 | -0.3% | -1.3% | -9.6% | |
| Q4 2018 | -1.5% | -0.8% | +1.5% | |
| Q3 2018 | +69.9% | +71.2% | +75.7% | |
| Q2 2018 | +0.5% | +4.7% | +31.7% | |
| Q1 2018 | -8.7% | -6.9% | +0.8% | |
| Q4 2017 | -4.9% | -8.5% | -16.2% | |
| Q3 2017 | -27.2% | -33.9% | -27.2% | |
| Q2 2017 | +13.7% | +38.8% | +57.1% | |
| Q1 2017 | -19.4% | -20.3% | -27.2% | |
| Q4 2016 | -1.2% | -1.7% | +6.2% | |
| Q3 2016 | -20.4% | -12.7% | -17.4% | |
| Q2 2016 | +14.6% | +10.3% | +6.8% | |
| Q1 2016 | +18.2% | — | — | |
| Q4 2015 | -24.0% | — | — | |
| Q3 2015 | +9.7% | — | — | |
| Q2 2015 | -17.2% | — | — | |
| Q1 2015 | -0.5% | — | — | |
| Q4 2014 | -16.4% | — | — | |
| Q3 2014 | +11.8% | — | — | |
| Q2 2014 | +2.6% | — | — | |
| Q1 2014 | -5.6% | — | — | |
| Q4 2013 | +2.2% | — | — | |
| Q3 2013 | +0.0% | — | — | |
| Q2 2013 | +5.7% | — | — | |
| Q1 2013 | -0.4% | — | — | |
| Q4 2012 | +0.0% | — | — | |
| Q3 2012 | -5.4% | — | — | |
| Q2 2012 | +2.9% | — | — | |
| Q1 2012 | +0.0% | — | — | |
| Q4 2011 | -12.7% | — | — | |
| Q3 2011 | -7.8% | — | — | |
| Q2 2011 | +8.9% | — | — | |
| Q1 2011 | -1.3% | — | — | |
| Q4 2010 | +2.7% | — | — | |
| Q3 2010 | +9.2% | — | — | |
| Q2 2010 | — | — | — | |
| Q1 2010 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro